non-obviousness

4 cases — ← All topics

Case Title Lower Court Docketed Status Flags Tags Question Presented
24-1132 Purdue Pharma L.P., et al. v. Accord Healthcare, Inc. Federal Circuit 2025-05-02 Denied federal-circuit non-obviousness obviousness patent-law pharmaceutical-innovation secondary-considerations Whether the objective indicia of non-obviousness should be analyzed flexibly to combat hindsight bias or subject to the Federal Circuit's rigid rules …
20-1258 Ono Pharmaceutical Co., Ltd., et al. v. Dana-Farber Cancer Institute, Inc. Federal Circuit 2021-03-11 Denied conception conception-standard federal-circuit-rule inventorship-correction joint-inventorship non-obviousness novelty patent-law prior-art Whether the Federal Circuit erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that …
18-1418 Senju Pharmaceutical Co., Ltd., et al. v. Akorn, Inc. Federal Circuit 2019-05-13 Denied 35-usc-144 federal-circuit mandate non-obviousness obviousness-standard opinion patent-appeal patent-appeals patent-law patent-trial-and-appeal-board rule-36 statutory-interpretation Whether 35 U.S.C. § 144's directive that the Federal Circuit shall issue ... its mandate and opinion' in all appeals from the Patent and Trademark Off…
18-823 ZUP, LLC v. Nash Manufacturing, Inc. Federal Circuit 2018-12-28 Denied Amici (1)Response Waived invention invention-evaluation legal-analysis long-felt-need non-obviousness obviousness obviousness-standard patent patent-invalidity patent-law prima-facie prior-art rebuttal secondary-considerations Whether evidence of 'secondary considerations' is less important in rebutting prima facie evidence of obviousness